Sai M, Kawanishi Y, Itoh Y, Aizawa S, Kawashima T, Koga M, Kuratsuji T, Toyama K
First Department of Internal Medicine, Tokyo Medical College.
Rinsho Ketsueki. 1990 Feb;31(2):245-8.
We present a patient with refractory anemia (RA) who developed Sweet's syndrome during the treatment of recombinant human granulocyte colony-stimulating factor (rhG-CSF). A 30-year-old man was admitted to the hospital for evaluation of anemia. He was diagnosed as MDS (RA). As a phase II study in MDS, rhG-CSF therapy was begun. Fever associated with cutaneous lesion developed over the left shoulder. Antibiotics showed no effects. Skin biopsy revealed Sweet's syndrome. This skin lesion disappeared thoroughly with discontinuance of G-CSF and administration of prednisolone. To examine whether Sweet's syndrome was related to the G-CSF therapy, we analyzed the effect of G-CSF on the function of patient's neutrophils. However, the function of patient's neutrophils was not activated by G-CSF administration.
我们报告一例难治性贫血（RA）患者，其在重组人粒细胞集落刺激因子（rhG-CSF）治疗期间发生了Sweet综合征。一名30岁男性因贫血评估入院。他被诊断为骨髓增生异常综合征（RA）。作为骨髓增生异常综合征的II期研究，开始了rhG-CSF治疗。左肩部出现伴有皮肤病变的发热。抗生素治疗无效。皮肤活检显示为Sweet综合征。停用G-CSF并给予泼尼松龙后，该皮肤病变完全消失。为了研究Sweet综合征是否与G-CSF治疗有关，我们分析了G-CSF对患者中性粒细胞功能的影响。然而，给予G-CSF并未激活患者中性粒细胞的功能。
